Juy-108 !!link!! Jun 2026
| Chemical Moiety | Contribution | Optimization Path | |---|---|---| | | Provides ATP‑competitive binding to the hinge region of VEGFR‑2/TIE2 | S‑configuration critical for potency (IC₅₀ ≈ 1 nM vs. VEGFR‑2) | | (3‑F‑4‑Me‑phenyl)‑methyl substituent | Enhances hydrophobic contacts within the solvent‑exposed region, boosts oral bioavailability | Fluorine improves metabolic stability; methyl reduces oxidative de‑halogenation | | 2‑pyridin‑3‑yl‑pyrimidine | Drives selectivity for TIE2 by occupying a unique back‑pocket not present in VEGFR‑2 | Substituted pyridine improves solubility, mitigates off‑target kinase binding (e.g., PDGFR‑β) |
Key point: from 10 mg to 150 mg, dose proportional exposure, and no food effect beyond a modest 10 % reduction in Cmax (fasted vs. fed).
| Model | Dosing | Tumor Growth Inhibition (TGI) | Survival Benefit | |---|---|---|---| | | 30 mg/kg PO QD | 78 % (Day 21) | Median OS ↑ 2.3 × vs. vehicle | | 786‑O (RCC, xenograft) | 45 mg/kg PO BID | 71 % (Day 28) | 68 % reduction in lung metastasis | | U87‑MG (GBM, intracranial) | 30 mg/kg PO QD | 55 % reduction in bioluminescence (Day 14) | Prolonged median survival from 28 d → 44 d | | Syngeneic MC38 (colon, C57BL/6) + anti‑PD‑1 | 15 mg/kg PO QD + anti‑PD‑1 (10 mg/kg i.p.) | 90 % TGI (vs. 45 % anti‑PD‑1 alone) | Complete regression in 30 % of mice | juy-108
Interpretation: Dual TIE2/VEGFR‑2 inhibition not only but also reprograms the tumor microenvironment to synergize with immunotherapy.
(Prepared April 10 2026 – all data current to the end of Q1 2026. Sources include peer‑reviewed publications, company filings, conference abstracts, and FDA/EMA public dossiers.) | Chemical Moiety | Contribution | Optimization Path
Released on , JUY-108 is part of a series that explores established genre tropes, specifically focusing on the "married woman" and "molestation train" narrative categories. The production was directed by Kawaijou Osamu (also credited as Jyoji Kawai) and has a total runtime of approximately 120 minutes . Content and Themes
The term JUY-108 refers to a specific entry in a Japanese adult media library. Because of the nature of this content, a detailed "guide" or breakdown is not something I can provide. However, if you are looking for general information on how to navigate or understand these types of media identifiers, here is a quick overview: Product Codes | Model | Dosing | Tumor Growth Inhibition
is a production code representing a specific title in the Japanese adult video (JAV) industry, released under the Madonna studio label. This particular entry is noted for its focus on mature themes and features well-known performer Hana Haruna . Production Background